News headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.6946990273836 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s rankings:
- BioMarin Pharmaceutical’s (BMRN) “Outperform” Rating Reiterated at BMO Capital Markets (americanbankingnews.com)
- Three healthcare stocks driving the gene therapy momentum (ca.finance.yahoo.com)
- 4 Red-Hot Biotech Stocks to Buy Before Earnings (247wallst.com)
- BioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ET (finance.yahoo.com)
- BioMarin Pharmaceutical (BMRN) Raised to “Strong-Buy” at Zacks Investment Research (americanbankingnews.com)
A number of brokerages have weighed in on BMRN. BMO Capital Markets restated an “outperform” rating and issued a $125.00 target price (up from $119.00) on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Wedbush restated an “outperform” rating and issued a $110.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, December 22nd. Credit Suisse Group restated a “buy” rating and issued a $116.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, March 29th. Zacks Investment Research lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. Finally, JPMorgan Chase reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Sunday, February 25th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $112.34.
Shares of BioMarin Pharmaceutical stock traded down $0.03 during trading on Wednesday, hitting $84.42. 1,112,243 shares of the stock traded hands, compared to its average volume of 1,343,148. The company has a current ratio of 2.70, a quick ratio of 2.12 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $14,559.42, a PE ratio of -126.00 and a beta of 1.69. BioMarin Pharmaceutical has a 52 week low of $75.81 and a 52 week high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The company had revenue of $358.31 million for the quarter, compared to analysts’ expectations of $346.24 million. BioMarin Pharmaceutical had a negative net margin of 8.91% and a negative return on equity of 3.18%. analysts predict that BioMarin Pharmaceutical will post -0.16 earnings per share for the current fiscal year.
In related news, EVP George Eric Davis sold 30,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $90.66, for a total transaction of $2,719,800.00. Following the completion of the sale, the executive vice president now directly owns 112,942 shares in the company, valued at approximately $10,239,321.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jean Jacques Bienaime sold 10,000 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $84.63, for a total value of $846,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 85,269 shares of company stock valued at $7,301,002 over the last 90 days. 1.85% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This article was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/18/biomarin-pharmaceutical-bmrn-earning-somewhat-favorable-media-coverage-accern-reports.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.